Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dose Modifications and Tolerability Associated with mCRC Treatment Regimens

March 7th 2024

Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.

FRESCO-2 Study Highlights

March 7th 2024

Medical experts provide key takeaways and impacts from the FRESCO-2 study.

Immunotherapy Success Signals Paradigm Shift Toward Nonoperative Management in Select GI Cancers

March 4th 2024

Michael J. Overman, MD, discusses the potential advantages of using nonoperative immunotherapy-based approaches in select gastrointestinal cancers.

A2B530 Receives FDA Orphan Drug Designation in CRC

March 4th 2024

The FDA has granted orphan drug designation to A2B530 for the treatment of select patients with colorectal cancer.

Dr Pedersen on Updates in mCRC Management

March 1st 2024

Katrina S. Pedersen, MD, MS, discusses key updates and FDA approvals from 2023 in metastatic colorectal cancer.

Compounding Impact of TAS-102 and Bevacizumab in mCRC Treatment

February 29th 2024

Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.

Fruquintinib MoA and Toxicity Profile Overview

February 29th 2024

Key safety considerations for the use of fruquintinib are explored.

Discordant dMMR/IHC Status Correlates With Improved Treatment Outcomes in CRC and Endometrial Cancer

February 27th 2024

Patients with mismatch repair–deficient, immunohistochemistry-intact colorectal cancer or endometrial cancer benefit from immune checkpoint inhibitors.

Dr Yaeger on the Implications of Data With Second-Line Sotorasib Plus Panitumumab in mCRC

February 27th 2024

Rona Yaeger, MD, discusses the implications of data with second-line sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.

Evaluating 3L Treatment Landscape Evolution

February 22nd 2024

Dr Parikh drives a conversation surrounding 3L treatment for patients diagnosed with metastatic colorectal cancer.

Overview of Current mCRC Treatment Landscape

February 22nd 2024

Medical experts open a discussion providing an update on the current impact of metastatic colorectal cancer and common treatment strategies.

FDA Grants Priority Review to Adagrasib/Cetuximab Combination Therapy in KRAS G12C–Mutant CRC

February 20th 2024

A sNDA for adagrasib plus cetuximab in advanced KRAS G12C–mutated colorectal cancer was granted priority review by the FDA.

Dr Kim on the Background of a Real-World Study of the Use of Regorafenib in mCRC

February 13th 2024

Richard Kim, MD, discusses a real-world investigation of long-term responses with regorafenib in metastatic colorectal cancer.

Complementary NGS Improves dMMR Detection With IHC in CRC and Endometrial Cancer

February 8th 2024

Amin Nassar, MD, and Elias Bou Farhat, MD, spotlight a study evaluating the accuracy and sensitivity of NGS mutation signature in assessing MMR status vs IHC testing.

Dr Yu discusses the ARCAD Nomogram in a Real-World CRC Population

February 2nd 2024

James Yu, MD, discusses the validation of the ARCAD nomogram in the real-world setting for patients with stage IV colorectal cancer.

Dr Yaeger on the Background of the CodeBreaK 101 Trial in mCRC

February 2nd 2024

Rona Yaeger, MD, discusses the rationale for launching an expansion cohort study based on findings from the CodeBreaK 101 study.

SCO-101 Plus FOLFIRI Shows Signs of Efficacy in Metastatic Colorectal Cancer

February 1st 2024

The combination of SCO-101 and FOLFIRI resulted in tumor reduction and increased progression-free survival in patients with metastatic colorectal cancer.

KRAS G12C–Targeted Therapies May Move Earlier in the mCRC Treatment Sequence

January 31st 2024

Rona Yaeger, MD, discusses a study of second-line sotorasib plus panitumumab in patients with KRAS G12C–mutated colorectal cancer.

Dr Stintzing on the Background of the Q-TWiST Analysis of Fruquintinib in mCRC

January 30th 2024

Sebastian Stintzing, MD, discusses treatment with fruquintinib plus best supportive care in the Q-TWIST analysis in metastatic colorectal cancer.

Dr Barzi on the Real-World Use of Triplet Chemotherapies in mCRC

January 22nd 2024

Afsaneh Barzi, MD, PhD, discusses the frontline use of FOLFOXIRI plus bevacizumab and subsequent therapies in patients with metastatic colorectal cancer.